Mark E. Bunnage - 10 Feb 2026 Form 4 Insider Report for VERTEX PHARMACEUTICALS INC / MA (VRTX)

Reporting relationship: EVP, Chief Scientific Officer
Issuer ticker: VRTX
Reported as of: 10 Feb 2026
Net transaction value: -$1,458,427
SEC form: 4
Accepted by SEC: 12 Feb 2026, 16:56:10 UTC
Prior SEC filing: 03 Feb 2026
Next SEC filing: 18 Feb 2026
Source filing: View source filing
Reporting owner signature: /s/ Christiana Stevenson, Attorney-in-Fact

Key filing fact

Mark E. Bunnage filed Form 4 for VERTEX PHARMACEUTICALS INC / MA (VRTX) on 12 Feb 2026.

Key facts

This page summarizes Mark E. Bunnage's Form 4 filing for VERTEX PHARMACEUTICALS INC / MA (VRTX).
2 reported transactions and 0 derivative rows are listed below.
Accepted by SEC: 12 Feb 2026, 16:56.

Change

Previous filing in this sequence was filed on 03 Feb 2026.
Current net transaction value: -$1,458,427.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0002100735 Primary reporting owner

Bunnage Mark E.

Relationship: EVP, Chief Scientific Officer
Address: C/O VERTEX PHARMACEUTICALS INCORPORATED, 50 NORTHERN AVENUE, BOSTON
Signature: /s/ Christiana Stevenson, Attorney-in-Fact
Signature date: 12 Feb 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

VRTX transaction

Common Stock

Tax liability

Transaction value: $527,898
Shares: -1,127
Change %: -7%
Price: $468.41
Shares after: 14,935
Date: 10 Feb 2026
Ownership: Direct

VRTX transaction

Common Stock

Sale

Transaction value: $930,529
Shares: -2,021
Change %: -14%
Price: $460.43
Shares after: 12,914
Date: 11 Feb 2026
Ownership: Direct
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 1 footnote

Footnote F1

Transaction made pursuant to Dr. Bunnage's company approved trading plan under Rule 10b5-1, which was entered into on 11/26/2025.